Author:
Saxena Shubhangi,Dagar Neha,Shelke Vishwadeep,Lech Maciej,Khare Pragyanshu,Gaikwad Anil Bhanudas
Subject
Drug Discovery,Pharmacology
Reference80 articles.
1. Dissection of metabolic reprogramming in polycystic kidney disease reveals coordinated rewiring of bioenergetic pathways;Podrini;Commun Biol,2018
2. Epidemiology of chronic kidney disease: an update 2022;Kovesdy;Kidney International Supplements,2022
3. Transition of acute kidney injury to chronic kidney disease: role of metabolic reprogramming;Zhu;Metabolism,2022
4. Metabolic reprogramming in kidney diseases: evidence and therapeutic opportunities;Li;Int J Nephrol,2021
5. RAAS inhibitors are not associated with mortality in COVID-19 patients: findings from an observational multicenter study in Italy and a meta-analysis of 19 studies;COVID-19 RISk and Treatments (CORIST) Collaboration;VascPharmacol,2020
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The AKI-to-CKD Transition: The Role of Uremic Toxins;International Journal of Molecular Sciences;2023-11-10